GH Research PLC (NASDAQ:GHRS) Given Average Rating of "Buy" by Brokerages

GH Research PLC (NASDAQ:GHRS - Get Free Report) has been given a consensus recommendation of "Buy" by the seven research firms that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued a report on the stock in the last year is $32.00.

GHRS has been the subject of several recent analyst reports. Royal Bank Of Canada assumed coverage on shares of GH Research in a research note on Friday, March 7th. They issued an "outperform" rating and a $31.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of GH Research in a report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of GH Research in a report on Friday, May 9th. Guggenheim decreased their price target on shares of GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Wall Street Zen cut shares of GH Research from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in shares of GH Research during the fourth quarter worth $44,000. Palumbo Wealth Management LLC purchased a new position in shares of GH Research during the first quarter worth $142,000. XTX Topco Ltd purchased a new position in shares of GH Research during the first quarter worth $169,000. Two Sigma Investments LP purchased a new position in shares of GH Research during the fourth quarter worth $117,000. Finally, Millennium Management LLC purchased a new position in shares of GH Research during the fourth quarter worth $145,000. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Price Performance

Shares of NASDAQ:GHRS traded down $0.15 during trading on Friday, reaching $11.84. 146,643 shares of the company were exchanged, compared to its average volume of 189,481. The firm has a market capitalization of $616.04 million, a PE ratio of -14.99 and a beta of 0.97. The business's fifty day simple moving average is $10.92 and its 200-day simple moving average is $10.44. GH Research has a 12-month low of $6.00 and a 12-month high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.42. On average, sell-side analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).